{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=107", "query": { "condition": "Relapsed, Refractory Malignant Neoplasms", "page": 107 }, "page_size": 10 }, "pagination": { "page": 107, "page_size": 10, "total_count": 3449, "total_pages": 345, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=108&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=106&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T18:49:45.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00363272", "title": "Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Spinal Cord Neoplasm", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ispinesib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 30, "start_date": "2006-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363272" }, { "nct_id": "NCT02273102", "title": "Study of TCP-ATRA for Adult Patients With AML and MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndromes", "Leukemia" ], "interventions": [ { "name": "Tranylcypromine", "type": "DRUG" }, { "name": "Tretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-03-02", "completion_date": "2020-07-01", "has_results": false, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273102" }, { "nct_id": "NCT06780137", "title": "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Gocatamig", "type": "BIOLOGICAL" }, { "name": "Ifinatamab Deruxtecan (I-DXd)", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 327, "start_date": "2025-02-27", "completion_date": "2029-02-15", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 9, "location_summary": "Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780137" }, { "nct_id": "NCT06458439", "title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Relapsed Diffuse Large B Cell Lymphoma", "Refractory Diffuse Large B-cell Lymphoma", "High-grade B-cell Lymphoma", "Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2024-09-24", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06458439" }, { "nct_id": "NCT05053607", "title": "Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Digital Health Coaching Program", "type": "BEHAVIORAL" }, { "name": "Fitbit", "type": "DEVICE" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE" ], "sponsor": "Pack Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-06-17", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05053607" }, { "nct_id": "NCT00051987", "title": "Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma" ], "interventions": [ { "name": "VELCADE TM (bortezomib) for Injection, or PS-341", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2002-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-02-11", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Pine Bluff, Arkansas + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Berkley", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00051987" }, { "nct_id": "NCT05362773", "title": "A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Acute Myeloid", "Myelodysplastic Syndromes", "Classical Hodgkin Lymphoma", "Leukemia, B-cell", "Leukemia, Hairy Cell", "Mastocytosis, Aggressive Systemic", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "MGD024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-07-13", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 7, "location_summary": "Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05362773" }, { "nct_id": "NCT06995872", "title": "Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "rhIL-15", "type": "DRUG" }, { "name": "Dinituximab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "3 Years to 35 Years" }, "enrollment_count": 40, "start_date": "2025-10-21", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995872" }, { "nct_id": "NCT00718809", "title": "Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Thymoma and Thymic Carcinoma", "Recurrent Thymoma and Thymic Carcinoma", "Stage III Thymoma", "Stage IVA Thymoma", "Stage IVB Thymoma" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2008-06", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-06-10", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 2, "location_summary": "Stanford, California • Indianapolis, Indiana", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00718809" }, { "nct_id": "NCT00005799", "title": "Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "B-cell Chronic Lymphocytic Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Childhood Renal Cell Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia", "Clear Cell Renal Cell Carcinoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Splenic Marginal Zone Lymphoma", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer", "T-cell Large Granular Lymphocyte Leukemia", "Type 1 Papillary Renal Cell Carcinoma", "Type 2 Papillary Renal Cell Carcinoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 55, "start_date": "1999-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-09-10", "last_synced_at": "2026-11-03T18:49:45.215Z", "location_count": 6, "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005799" } ] }